Is  ||| S:0 E:3 ||| VBZ
pentoxifylline  ||| S:3 E:18 ||| JJ
effective  ||| S:18 E:28 ||| JJ
in  ||| S:28 E:31 ||| IN
alcoholic  ||| S:31 E:41 ||| JJ
hepatitis ||| S:41 E:50 ||| NN
?  ||| S:50 E:52 ||| VBZ
Â–First  ||| S:52 E:59 ||| RB
update  ||| S:59 E:66 ||| VB
This  ||| S:66 E:71 ||| DT
article  ||| S:71 E:79 ||| NN
updates  ||| S:79 E:87 ||| NNS
the  ||| S:87 E:91 ||| DT
June  ||| S:91 E:96 ||| NNP
2014  ||| S:96 E:101 ||| CD
Living  ||| S:101 E:108 ||| NNP
FRISBEE  ||| S:108 E:116 ||| NNP
( ||| S:116 E:117 ||| -LRB-
Living  ||| S:117 E:124 ||| NNP
FRISBEE ||| S:124 E:131 ||| NNP
:  ||| S:131 E:133 ||| :
Living  ||| S:133 E:140 ||| NNP
FRIendly  ||| S:140 E:149 ||| NNP
Summary  ||| S:149 E:157 ||| NNP
of  ||| S:157 E:160 ||| IN
the  ||| S:160 E:164 ||| DT
Body  ||| S:164 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
Evidence  ||| S:172 E:181 ||| NN
using  ||| S:181 E:187 ||| VBG
Epistemonikos ||| S:187 E:200 ||| NNP
) ||| S:200 E:201 ||| -RRB-
.  ||| S:201 E:203 ||| .
It  ||| S:203 E:206 ||| PRP
incorporates  ||| S:206 E:219 ||| VBZ
a  ||| S:219 E:221 ||| DT
new  ||| S:221 E:225 ||| JJ
systematic  ||| S:225 E:236 ||| JJ
review  ||| S:236 E:243 ||| NN
identifying  ||| S:243 E:255 ||| VBG
one  ||| S:255 E:259 ||| CD
study  ||| S:259 E:265 ||| NN
not  ||| S:265 E:269 ||| RB
included  ||| S:269 E:278 ||| VBN
in  ||| S:278 E:281 ||| IN
previous  ||| S:281 E:290 ||| JJ
reviews ||| S:290 E:297 ||| NNS
.  ||| S:297 E:299 ||| .
The  ||| S:299 E:303 ||| DT
new  ||| S:303 E:307 ||| JJ
evidence  ||| S:307 E:316 ||| NN
leads  ||| S:316 E:322 ||| VBZ
to  ||| S:322 E:325 ||| TO
substantial  ||| S:325 E:337 ||| JJ
changes  ||| S:337 E:345 ||| NNS
in  ||| S:345 E:348 ||| IN
the  ||| S:348 E:352 ||| DT
existing  ||| S:352 E:361 ||| JJ
evidence ||| S:361 E:369 ||| NN
.  ||| S:369 E:371 ||| .
Pentoxifylline  ||| S:371 E:386 ||| NNP
is  ||| S:386 E:389 ||| VBZ
an  ||| S:389 E:392 ||| DT
inhibitor  ||| S:392 E:402 ||| NN
of  ||| S:402 E:405 ||| IN
tumor  ||| S:405 E:411 ||| NN
necrosis  ||| S:411 E:420 ||| NN
factor ||| S:420 E:426 ||| NN
,  ||| S:426 E:428 ||| ,
and  ||| S:428 E:432 ||| CC
has  ||| S:432 E:436 ||| VBZ
been  ||| S:436 E:441 ||| VBN
proposed  ||| S:441 E:450 ||| VBN
as  ||| S:450 E:453 ||| IN
treatment  ||| S:453 E:463 ||| NN
for  ||| S:463 E:467 ||| IN
alcoholic  ||| S:467 E:477 ||| JJ
hepatitis ||| S:477 E:486 ||| NN
.  ||| S:486 E:488 ||| .
However ||| S:488 E:495 ||| RB
,  ||| S:495 E:497 ||| ,
it  ||| S:497 E:500 ||| PRP
is  ||| S:500 E:503 ||| VBZ
not  ||| S:503 E:507 ||| RB
clear  ||| S:507 E:513 ||| JJ
if  ||| S:513 E:516 ||| IN
it  ||| S:516 E:519 ||| PRP
is  ||| S:519 E:522 ||| VBZ
effective ||| S:522 E:531 ||| JJ
,  ||| S:531 E:533 ||| ,
or  ||| S:533 E:536 ||| CC
if  ||| S:536 E:539 ||| IN
it  ||| S:539 E:542 ||| PRP
adds  ||| S:542 E:547 ||| VBZ
benefit  ||| S:547 E:555 ||| NN
to  ||| S:555 E:558 ||| TO
the  ||| S:558 E:562 ||| DT
treatment  ||| S:562 E:572 ||| NN
with  ||| S:572 E:577 ||| IN
corticosteroids ||| S:577 E:592 ||| NN
.  ||| S:592 E:594 ||| .
Searching  ||| S:594 E:604 ||| VBG
in  ||| S:604 E:607 ||| IN
Epistemonikos  ||| S:607 E:621 ||| NNP
database ||| S:621 E:629 ||| NN
,  ||| S:629 E:631 ||| ,
which  ||| S:631 E:637 ||| WDT
is  ||| S:637 E:640 ||| VBZ
maintained  ||| S:640 E:651 ||| VBN
by  ||| S:651 E:654 ||| IN
screening  ||| S:654 E:664 ||| VBG
30  ||| S:664 E:667 ||| CD
databases ||| S:667 E:676 ||| NN
,  ||| S:676 E:678 ||| ,
we  ||| S:678 E:681 ||| PRP
identified  ||| S:681 E:692 ||| VBD
three  ||| S:692 E:698 ||| CD
systematic  ||| S:698 E:709 ||| JJ
reviews  ||| S:709 E:717 ||| NNS
including  ||| S:717 E:727 ||| VBG
eight  ||| S:727 E:733 ||| CD
randomized  ||| S:733 E:744 ||| NNS
controlled  ||| S:744 E:755 ||| VBN
trials  ||| S:755 E:762 ||| NNS
addressing  ||| S:762 E:773 ||| VBG
the  ||| S:773 E:777 ||| DT
question  ||| S:777 E:786 ||| NN
of  ||| S:786 E:789 ||| IN
this  ||| S:789 E:794 ||| DT
article ||| S:794 E:801 ||| NN
.  ||| S:801 E:803 ||| .
We  ||| S:803 E:806 ||| PRP
combined  ||| S:806 E:815 ||| VBD
the  ||| S:815 E:819 ||| DT
evidence  ||| S:819 E:828 ||| NN
using  ||| S:828 E:834 ||| VBG
meta-analysis  ||| S:834 E:848 ||| JJ
and  ||| S:848 E:852 ||| CC
generated  ||| S:852 E:862 ||| VBD
a  ||| S:862 E:864 ||| DT
summary  ||| S:864 E:872 ||| NN
of  ||| S:872 E:875 ||| IN
findings  ||| S:875 E:884 ||| NNS
following  ||| S:884 E:894 ||| VBG
the  ||| S:894 E:898 ||| DT
GRADE  ||| S:898 E:904 ||| NNP
approach ||| S:904 E:912 ||| NN
.  ||| S:912 E:914 ||| .
We  ||| S:914 E:917 ||| PRP
concluded  ||| S:917 E:927 ||| VBD
pentoxifylline  ||| S:927 E:942 ||| VBN
probably  ||| S:942 E:951 ||| RB
leads  ||| S:951 E:957 ||| VBZ
to  ||| S:957 E:960 ||| TO
little  ||| S:960 E:967 ||| JJ
or  ||| S:967 E:970 ||| CC
no  ||| S:970 E:973 ||| DT
difference  ||| S:973 E:984 ||| NN
in  ||| S:984 E:987 ||| IN
mortality  ||| S:987 E:997 ||| NN
in  ||| S:997 E:1000 ||| IN
alcoholic  ||| S:1000 E:1010 ||| JJ
hepatitis ||| S:1010 E:1019 ||| NN
.  ||| S:1019 E:1021 ||| .
Abstract  ||| S:1021 E:1030 ||| JJ
available  ||| S:1030 E:1040 ||| JJ
from  ||| S:1040 E:1045 ||| IN
the  ||| S:1045 E:1049 ||| DT
publisher ||| S:1049 E:1058 ||| NN
. ||| S:1058 E:1059 ||| .
